References
- World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions. Updated 9 July 2020. [cited 2020 Oct 20]. https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions
- World Health Organization. Rolling updates on coronavirus disease (COVID-19). Updated 31 Jul 2020. [cited 2020 Oct 20]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Updated 20 Oct 2020. [cited 2020 Oct 20]. https://covid19.who.int
- Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–362.
- Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
- Chen LD, Zhang ZY, Wei XJ, et al. Association between cytokine profiles and lung injury in COVID-19 pneumonia. Respir Res. 2020;21(1):201.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
- Russano M, Citarella F, Napolitano A, et al. COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. Expert Opin Biol Ther. 2020;20(9): 959–964.
- Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020 Jun;215:108427.
- Zhou Y, Fu B, Zheng X, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7(6): 998–1002.
- Sinha P, Mostaghim A, Bielick CG, et al. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. Int J Infect Dis. 2020;99:28–33.
- The WHO Collaborating Centre for Drug Statistics Methodology. Updates included in ATC/DDD index. Updated 16 Dec 2019. [cited 2020 Oct 22]. https://www.whocc.no/atc_ddd_index/?code=L04AC&showdescription=no
- Electronic Medicines Compendium (EMC). RoActemra 20mg/ml concentrate for solution for infusion. Updated 23 Jul 2020. [cited 2020 Oct 22]. https://www.medicines.org.uk/emc/product/6673/smpc#gref
- Food and Drug Administration. ACTEMRA (tocilizumab) injection: prescribing INFORMATION. Updated 2017 Aug. [cited 2020 Oct 22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf
- Tocilizumab. Updated 29 Jul, 2015. [cited 2020 Oct 25]. https://www.pharmacodia.com/yaodu/html/v1/biologics/5f1d3986fae10ed2994d14ecd89892d7.html#:~:text=Tocilizumab%20was%20first%20approved%20by,)%20on%20March%2026%2C%202013
- Antwi-Amoabeng D, Kanji Z, Ford B, et al. Clinical outcomes in COVID-19 patients treated with tocilizumab: an individual patient data systematic review. J Med Virol. 2020;92(11):2516–2522.
- De Rossi N, Scarpazza C, Filippini C, et al. Early use of low dose tocilizumab in patients with COVID-19: a retrospective cohort study with a complete follow-up. EClinicalMedicine. 2020 Aug;25:100459.
- Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e474–e484.
- Keske Ş, Tekin S, Sait B, et al. Appropriate use of tocilizumab in COVID-19 infection. Int J Infect Dis. 2020 Oct;99:338–343.
- Menzella F, Fontana M, Salvarani C, et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020 Sep 29;24(1):589.
- Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes. Chest. 2020 Oct;158(4):1397–1408.
- Samaee H, Mohsenzadegan M, Ala S, et al. Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. Int Immunopharmacol. 2020 Sep 16;89(Pt A):107018.
- Tomasiewicz K, Piekarska A, Stempkowska-Rejek J, et al. Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. Expert Rev Anti Infect Ther. 2020 Aug 1;1–8. DOI:https://doi.org/10.1080/14787210.2020.1800453.
- Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single-center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020 Jul;19(7):102568.
- Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-center retrospective cohort study. Eur J Intern Med. 2020 Jun;76:43–49.
- Lan SH, Lai CC, Huang HT, et al. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020 Sep;56(3):106103. Epub 2020 Jul 23. PMID: 32712333; PMCID: PMC7377685.
- Morena V, Milazzo L, Oreni L, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020 Jun;76:36–42.
- Tsai A, Diawara O, Nahass RG, et al. Impact of tocilizumab administration on mortality in severe COVID-19. Sci Rep. 2020;10(1):19131.
- Alattar R, Ibrahim TBH, Shaar SH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020 May;5. DOI:https://doi.org/10.1002/jmv.25964.
- Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol. 2020 Aug;129:104444.
- Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Dec 10 ;383(24):2333–2344.
- Uppsala Monitoring Centre: WHOProgramme for International Drug Monitoring. VigiBase. [cited 2020 Oct 27]. https://www.who-umc.org/vigibase/vigibase
- Uppsala Monitoring Centre. VigiBase: signaling harm and pointing to safer use. [cited 2020 Oct 28]. https://www.who-umc.org/vigibase/vigibase/vigibase-signalling-harm-and-pointing-to-safer-use
- World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. Updated 17 Aug 2020. [cited 2020 Oct 28]. https://www.whocc.no
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities(MedDRA). [cited 2020 Oct 28]. https://www.meddra.org/how-to-use/support-documentation/english/welcome
- Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999 Feb;20(2):109–117.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). MedDRA Hierarchy. [cited 2020 Oct 28]. https://www.meddra.org/how-to-use/basics/hierarchy
- Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020 Dec 3;383(23):2255–2273.
- Zhu Z, Cai T, Fan L, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020 Jun;95:332–339.
- Narasaraju T, Yang E, Samy RP, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol. 2011 Jul;179(1):199–210.
- Wang J, Jiang M, Chen X, et al. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020 Jul;108(1):17–41.
- Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020 Jun 1;217(6):e20200652.
- Lefrançais E, Looney MR. Neutralizing extracellular histones in acute respiratory distress syndrome. A new role for an endogenous pathway. Am J Respir Crit Care Med. 2017 Jul 15;196(2):122–124.
- Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020 Jun 4;5(11):e138999.
- Bordon J, Aliberti S, Fernandez-Botran R, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis. 2013 Feb;17(2):e76–83.
- Miles K, Clarke DJ, Lu W, et al. Dying and necrotic neutrophils are anti-inflammatory secondary to the release of alpha-defensins. J Immunol. 2009 Aug 1;183(3):2122–2132.
- Simon HU. Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev. 2003 Jun;193(1):101–110.
- Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: a Randomized Clinical Trial. JAMA Intern Med. 2021 Jan 1;181(1):24–31.
- Rimland CA, Morgan CE, Bell GJ, et al. Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center. medRxiv. 2020. DOI:https://doi.org/10.1101/2020.05.13.20100404.
- Gatti M, Fusaroli M, Caraceni P, et al. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. Br J Clin Pharmacol. 2021 Mar;87(3):1533–1540.
- Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. PloS One. 2020;15(8):e0237693.
- Gorgolas M, Cabello A, Prieto Perez L, et al. Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia. When late administration is too late. medRxiv. 2020. DOI:https://doi.org/10.1101/2020.06.13.20130088.
- Kimmig LM, Wu D, Gold M, et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Front Med (Lausanne). 2020 Oct;7:583897.
- Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020 Jul 11;ciaa954. DOI:https://doi.org/10.1093/cid/ciaa954.
- Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017 Jul;13(7):399–409.
- Başaran S, Şimşek-Yavuz S, Meşe S, et al. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: a prospective cohort study with multivariate analysis of factors affecting the antibody response. Int J Infect Dis. 2021 Apr;105:756–762.
- Cassese G, Arce S, Hauser AE, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol. 2003 Aug 15;171(4):1684–1690.
- Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988 Feb 1;167(2):332–344.
- Masiá M, Fernández-González M, Padilla S, et al. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: a prospective cohort study. EBioMedicin. 2020 Oct;60:102999.
- Cabanov A, Flood BA, Bloodworth J, et al. Abstract S04-02: treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection. Clin Cancer Res. 2020 September 15;26(18 Supplement):S04–02.
- Mori S, Ueki Y, Hirakata N, et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012 Dec;71(12):2006–2010.
- Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe COVID-19 Patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020 May 9;8(5):695.
- Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020 May-Jun;38(3):529–532.
- Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970–10975.
- Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, et al. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study. medRxiv. 2020. https://doi.org/10.1101/2020.05.07.20094599
- Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. Br Med J. 2021;372:n84.